KA
MRNA icon

Kovack Advisors’s Moderna MRNA Stock Holding History

Kovack Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
3,995
-6,385
-62% -$330K 0.01% 807
2026
Q1 		$523K Buy
+10,380
New +$484K 0.03% 573
2024
Q4 		– Sell
-5,844
Closed -$391K – 630
2024
Q3 		$391K Buy
5,844
+3,946
+208% +$362K 0.04% 366
2024
Q2 		$225K Sell
1,898
-833
-31% -$105K 0.02% 497
2024
Q1 		$291K Buy
2,731
+23
+0.8% +$2.32K 0.04% 358
2023
Q4 		$269K Sell
2,708
-662
-20% -$55.7K 0.03% 445
2023
Q3 		$348K Sell
3,370
-27
-0.8% -$3.01K 0.05% 347
2023
Q2 		$413K Sell
3,397
-1,522
-31% -$203K 0.05% 337
2023
Q1 		$755K Buy
4,919
+102
+2% +$16.8K 0.1% 200
2022
Q4 		$865K Sell
4,817
-648
-12% -$106K 0.13% 177
2022
Q3 		$646K Buy
5,465
+70
+1% +$10.6K 0.09% 232
2022
Q2 		$771K Sell
5,395
-705
-12% -$101K 0.1% 211
2022
Q1 		$1.05M Sell
6,100
-739
-11% -$124K 0.11% 204
2021
Q4 		$1.74M Sell
6,839
-3,322
-33% -$971K 0.17% 135
2021
Q3 		$3.91M Buy
10,161
+1,914
+23% +$706K 0.43% 39
2021
Q2 		$1.94M Sell
8,247
-113
-1% -$20.2K 0.22% 123
2021
Q1 		$1.09M Sell
8,360
-185
-2% -$26.8K 0.14% 168
2020
Q4 		$893K Sell
8,545
-817
-9% -$82.7K 0.13% 180
2020
Q3 		$662K Buy
9,362
+5,691
+155% +$397K 0.12% 188
2020
Q2 		$236K Buy
+3,671
New +$201K 0.05% 363

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Kovack Advisors's MRNA Position: Q2 2026 in Review

Kovack Advisors reduced its Moderna (MRNA) stake by 62% in Q2 2026, selling an estimated $330K and leaving 3,995 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #807.

Kovack Advisors first reported a position in MRNA in Q2 2020 and has held it in 20 quarters since. The position peaked at $3.91M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Kovack Advisors held 3,995 shares of Moderna worth $290K as of Q2 2026.
  • Kovack Advisors sold 6,385 Moderna shares in Q2 2026, an estimated $330K.
  • Moderna made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #807 holding.
  • Kovack Advisors first reported a position in Moderna in Q2 2020 and has held it in 20 quarters since.
  • Kovack Advisors's Moderna position peaked at $3.91M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.